Table 4 Adverse events.

From: Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy

Parameters

eRFA + CT (n = 40)

CT (n = 26)

P-value

Cholangitis during therapy

29 (72.5)

14 (53.8)

0.031

ERCP associated

11 (27.5)

9 (34.6)

0.539

Pancreatitis

4 (10.0)

2 (7.7)

0.750

Cholangitis

7 (17.5)

3 (11.5)

0.257

Biloma

1 (2.5)

0 (0)

0.417

Bleeding

3 (7.5)

4 (15.4)

0.420

Abscess

1 (2.5)

1 (3.8)

0.755

eRFA associated

6 (15.0)

–

–

Cholangitis

5 (12.5)

–

–

Abscess

1 (2.5)

–

–

Hematologic toxic effects

Thrombocytopenia

9 (22.5)

10 (38.5)

0.162

Neutropenia

4 (10.0)

4 (15.4)

0.702

Anemia

10 (25.0)

11 (42.3)

0.140

Leucopenia

6 (15.0)

3 (11.5)

0.689

Nephrotoxicity

3 (7.5)

0 (0)

0.273

Fatigue

3 (7.5)

2 (7.7)

0.977

Thromboembolic event

3 (7.5)

5 (19.2)

0.247

  1. Data are presented as absolute frequency with relative frequency in parentheses.
  2. Adverse events were registered if they required intervention or adaptation of therapy (CTCAE v4.0, grades 3–5).
  3. ERCP endoscopic retrograde cholangiopancreatography, eRFA endobiliary radiofrequency ablation.
  4. P values refer to Chi-squared test or Fisher exact performed between groups eRFA + CT and CT.
Back to article page